New FDA Guidance Aims to Boost Access to Opioid-Reversal Drug Naloxone
The US Food and Drug Administration (FDA) has issued guidance that will make it easier for harm reduction programs to distribute the opioid-reversal drug naloxone. The new guidance exempts harm reduction programs from certain requirements of the drug supply chain security act for the distribution of FDA-approved naloxone products during the opioid public health crisis.
@hinisha While the guidance supports harm reduction programs' ability to acquire naloxone, it does not address other challenges to access that communities face, including the current prescription-only status of FDA-approved naloxone products. Thus, there is still more work ahead of us as deaths from drug overdoses remain at historically high levels